Aligos Therapeutics (ALGS) Set to Announce Earnings on Wednesday

Aligos Therapeutics (NASDAQ:ALGS) is scheduled to be releasing its earnings data after the market closes on Wednesday, November 6th. Analysts expect Aligos Therapeutics to post earnings of ($2.15) per share for the quarter.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of ($4.00) by $4.75. Aligos Therapeutics had a negative return on equity of 110.59% and a negative net margin of 1,100.48%. The company had revenue of $1.06 million for the quarter. During the same period last year, the firm posted ($10.75) EPS. On average, analysts expect Aligos Therapeutics to post $-8 EPS for the current fiscal year and $-13 EPS for the next fiscal year.

Aligos Therapeutics Trading Up 1.8 %

NASDAQ ALGS traded up $0.17 on Tuesday, hitting $9.65. 33,013 shares of the stock were exchanged, compared to its average volume of 38,475. The company’s 50-day moving average price is $10.06 and its two-hundred day moving average price is $12.80. Aligos Therapeutics has a 52-week low of $6.76 and a 52-week high of $30.00.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $75.00 target price on shares of Aligos Therapeutics in a research note on Wednesday, October 23rd.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).